Nuevocor operates as a preclinical-stage biotech company.
Nuevocor has raised $45.0M in total funding. The most recent round was Series B. The last funding was announced in May 2025.
Nuevocor's investors include Highlight Capital, Kurma Partners, Boehringer Ingelheim Venture Fund, EDBI, Angelini Ventures.
Nuevocor is headquartered in Singapore, Singapore.
Nuevocor operates as a preclinical-stage biotech company.
Nuevocor is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nuevocor — Funding & Investors." VCBacked, May 6, 2025, https://www.vcbacked.co/company/nuevocor. Accessed October 29, 2026.
VCBacked. (2025). Nuevocor — Funding & Investors. Retrieved October 29, 2026, from https://www.vcbacked.co/company/nuevocor
{{cite web |title=Nuevocor — Funding & Investors |url=https://www.vcbacked.co/company/nuevocor |website=VCBacked |access-date=October 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated